PubMed ID:
29599296
Public Release Type:
Journal
Publication Year: 2018
Affiliation: University of California San Francisco, San Francisco, CA mandana.khalili@ucsf.edu.; University of Washington, Seattle, WA.; University of Pittsburgh, Pittsburgh, PA.; University of Toronto, Toronto, Ontario, Canada.; National Institutes of Health, Bethesda, MD.; Massachusetts General Hospital, Boston, MA.; University of California San Francisco, San Francisco, CA.; Washington University School of Medicine in St. Louis, St. Louis, MO.; Virginia Commonwealth University, Richmond, VA.; University of Michigan, Ann Arbor, MI.
DOI:
https://doi.org/10.2337/dc18-0040
Authors:
Khalili Mandana, Shuhart Margaret C, Lombardero Manuel, Feld Jordan J, Kleiner David E, Chung Raymond T, Terrault Norah A, Lisker-Melman Mauricio, Sanyal Arun, Lok Anna S
Request IDs:
20876
,
21197
Studies:
Hepatitis B Research Network Adult Cohort Study
Metabolic syndrome (MS) is prevalent and is associated with adverse outcomes of liver disease. We evaluated the prevalence of MS and its influence on alanine aminotransferase (ALT) levels and fibrosis, as estimated by the aspartate aminotransferase-to-platelet ratio index (APRI), in a large, multiethnic North American cohort with chronic hepatitis B (HBV) infection.